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Abstract
Background: Depletion of CD25+ Tregs improves anti-tumor immunity in preclinical models. Denileukin diftitox is a
recombinant fusion protein of human IL-2 and diptheria toxin fragment that also can kill CD25+ T cells. Prior clinical
trials of denileukin diftitox suggested reduction of FoxP3+ Tregs and some clinical responses.
Method: To investigate the immunologic effects of denileukin difitox on vaccine-specific immune responses in
melanoma, a randomized clinical trial of single dose denileukin diftitox prior to vaccination versus vaccination alone
in subjects with HLA-A2+ metastatic melanoma was performed. Treatment included randomization to a 4-peptide
vaccine (Melan-A, gp100, MAGE3 and NA17 with GM-CSF emulsified in Montanide) alone or after single dose of
denileukin diftitox (18 mcg/kg). Vaccine was given every 2 weeks for 3 doses and, absent clinical progression,
continued every 2 weeks. Blood and tumor biopsies were obtained pretreatment and after 3 vaccinations for
immunologic assessments.
Results: In 17 treated subjects there were no drug-related G3-4 adverse events. One partial response and 8 stable disease
were observed in 9 subjects (4 DD: 5 vaccine only) with no impact of denileukin diftitox on time to progression. Total
peripheral Tregs were not significantly altered, and in 1 patient biopsy intra-tumoral FoxP3 transcripts were not reduced
following denileukin diftitox. ELISA for IL2R-α demonstrated no impact on outcomes by soluble CD25 level. Immune
monitoring suggested the development of modest vaccine-specific CD8+ T cell responses in the control group, however
immunization efficacy was actually reduced in the denileukin diftitox group.
Conclusion: Our results indicate that denileukin diftitox did not effectively deplete Tregs, augment T cell responses, or
improve clinical activity in melanoma. Clinicaltrials.gov ID: NCT00515528; Registered August 9, 2007.
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Background
The presence of antigens expressed preferentially on tumor
cells has suggested tumor-specific vaccination as an immu-
notherapeutic approach for the treatment of cancer. Vac-
cines against cancer antigens including Melan-A, gp100,
MAGE, and NA17 have been associated with specific T cell
immunity and occasional clinical responses [1, 2]. Various
efforts have been made to improve vaccine efficacy in
cancer. One approach, emulsification of granulocyte-
macrophage colony-stimulating factor (GM-CSF) in
Montanide, has been suggested to increase CD8+ T
cell priming in murine models [3]. In subjects with
melanoma, the administration of peptides emulsified
in Montanide and GM-CSF has demonstrated signifi-
cant induction of antigen-specific CD8+ T cells [4].
Immunologic correlates of patient response to peptide
vaccines are incompletely understood, with some sub-
jects manifesting increased peptide-specific T cell re-
sponses as detected in the peripheral blood but no
regression of tumor. This general observation has sug-
gested that mechanisms downstream from initial T cell
priming may limit the effector phase of the anti-tumor
immune response, thus blunting therapeutic efficacy.
One mechanism of suppression of effector T cell func-
tion may be the FoxP3+CD4+CD25+ regulatory T cell
(Treg) population. Treatment of tumor-bearing mice
with anti-CD25 antibody can render mice capable of
rejecting progressively growing tumors [5]. Additionally,
subjects with cancer have been described to have in-
creased Treg cells in both circulation and in the tumor
microenvironment [6] with both of these associating
with poor prognosis in some studies [7].
Denileukin diftitox (DAB389IL-2 or ONTAK®) is a re-
combinant fusion protein between human interleukin-2
(IL-2) and a fragment of diptheria toxin [8]. It was devel-
oped as an agent to kill T cell lymphoma cells that
express the IL-2 receptor. [9] However, evidence sug-
gests that denileukin diftitox also can kill normal T cells
that express CD25. Because the majority of Tregs ex-
press high levels of CD25, it has been hypothesized that
the greatest immunologic impact of denileukin diftitox
may be on depleting Treg cells. A previous study of sin-
gle dose denileukin diftitox followed by vaccination with
tumor RNA-transfected dendritic cells noted a decrease
in circulating CD4+CD25+ T cells with a greater magni-
tude of the specific immune response to the vaccine
relative to no denileukin diftitox treatment [10]. In con-
trast, denileukin diftitox administered on a 5 day sched-
ule failed to deplete CD4+CD25+ T cells from the blood
of subjects with melanoma, [11] suggesting that a differ-
ence in dose or schedule could be important.
Based on the above discrepancies in the literature with
denileukin diftitox, we developed a clinical protocol of
administration of a single dose of denileukin diftotox
prior to vaccination with a multipeptide melanoma anti-
gen vaccine, compared to vaccine therapy alone. Herein
we report on the translational biomarker analyses of this
randomized phase II study.
Methods
Eligibility criteria
All study subjects provided voluntary written informed
consent. The protocol and all amendments were approved
by University of Chicago Institutional Review Board. The
study was registered as ClinicalTrials.gov Identifier: NCT0
0515528. Vaccine preparation was performed at the Uni-
versity of Chicago Human Immunological Monitoring/
Current Good Manufacturing Practices Facility, and deni-
leukin diftitox was provided by Eisai.
Eligible subjects had stage IIIC or IV histologically
confirmed melanoma and expression of HLA-A2, either
by flow cytometry or by standard HLA typing. Study
subjects could have had any number of prior treatments
but could not have a history of autoimmune disease.
Subjects with a history of brain metastases were eligible
if these were treated and stable without corticosteroids
for 4 weeks. Karnofsky performance status of ≥80 % was
required as well as adequate hepatic, cardiac, renal and
hematologic function defined as absolute neutrophil
count ≥1500/μl, platelets ≥ 100,000/μl, and hemoglobin ≥
10 g/dl. Lactate dehydrogenase was required to be less
than 1.25 times the institutional upper limit of normal.
No history of Human Immunodeficiency Virus or viral
hepatitis B/C was allowed. Pretreatment biopsy was re-
quired except when deemed unsafe, and the tumor must
have expressed at least two of the vaccine antigens (Melan-
A, gp100, MAGE, and NA17) as determined by immuno-
histochemical staining of 1+ or greater for Melan-A and
gp100, and/or antigen expression by RT-PCR on baseline
fresh biopsies. Women of childbearing potential were re-
quired to have a negative serum pregnancy test, and sub-
jects of both genders were required to practice adequate
birth control during protocol participation.
Clinical trial design
The clinical trial design was an open-label randomized
phase II single institution study comparing administra-
tion of a four-peptide melanoma vaccine alone or after a
single dose of denileukin diftitox in subjects with melan-
oma. Subjects were randomized 1:1 to either cohort A
or B. Subjects in cohort A (vaccine alone) received
vaccine immunization injected intra-dermally or sub-
cutaneously on day 1. The vaccine was an emulsification
consisting of 250 mcg each of the following peptides:
Melan-A, gp100, MAGE-3, and NA17 as well as GM-CSF
125 mcg and Montanide. A second and third vaccination
was given at 2 weeks and 4 weeks after the first. If there
was no evidence of cancer progression, additional courses
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of three vaccinations administered at 2 week intervals
were administered until disease progression. Subjects in
cohort B received the same vaccination strategy but
additionally received a single dose of denileukin difti-
tox (18 mcg/kg) 4 days prior to the first vaccine ad-
ministration. The primary endpoints of the study were
the ability of denileukin diftitox to reduce the num-
bers of circulating and tumor-infiltrating Tregs, as
well as to increase the frequencies of vaccine-induced
antigen-specific T cells. Secondary endpoints were to
examine an interaction with soluble circulating CD25,
toxicity assessment, and an early evaluation of clinical
activity with the combination therapy.
Toxicity was graded in accordance with the Common
Terminology Criteria for Adverse Events version 2.0.
Dose-limiting toxicities were defined as ≥Grade 3 in
addition to Grade 2 or higher autoimmunity or visual
impairment (both being criteria for study withdrawal).
Dose could be delayed up to 2 weeks for toxicity prior
to removal of the subject from the study. Response was
evaluated every 6 weeks based on Response Evaluation
In Solid Tumor (RECIST) version 1.1.
Blood sample collection and storage
Heparinized blood was drawn before treatment, monthly
during the vaccination, and at the end of the study. For
patients randomized to denileukin diftitox arm, an add-
itional blood sample was drawn 4 days after denileukin
diftitox administration. All the blood samples were col-
lected prior to a given treatment administration. PBMCs
were isolated using Lymphoprep gradient centrifugation,
aliquoted, and cryopreserved for later use. Serum sam-
ples were also collected before treatment and at the end
of the study and stored at -80 °C until analysis.
ELISA for soluble IL-2 receptor alpha (sIL-2R-α)
Serum sample were collected before the treatment and
at the end of the study from each patient. The sIL-2R-α
level was detected using the Human CD25/IL-2 R alpha
Quantikine ELISA Kit (R & D Systems, Inc.)
Flow cytometric analysis for peripheral Tregs
The fluorescence-activated cell sorting (FACS) analysis
of Treg numbers were carried out using Treg detection
kits from Miltenyi Biotech. Briefly, the achieved PBMCs
were thawed, washed, counted, and resuspended in
FACS buffer (PBS + 0.5 % BSA) at 10 x 106/ml. anti-CD4
and anti-CD25 antibodies were added to 100 ml PBMCs
and kept for 10 min in the dark in the refrigerator. Cells
were washed and fixed in cold, freshly prepared Fix-
ation/Permeablilization buffer for 30 min in the dark in
the refrigerator. Cells were then washed and resus-
pended in cold Permeabilization buffer. Blocking Re-
agent and FoxP3 antibody were added and incubated for
30 min in the dark in the refrigerator. Cells were washed
and analyzed on MACSQuant analyzer (Miltenyi Biotec).
The lymphocytes were gated based on FSC and SSC pa-
rameters, CD4+ cells were gated in the lymphocytes gate;
CD25hi FoxP3+ cells were gated inside the CD4+ popula-
tion. Treg numbers were calculated by multiply PBMCs
numbers with % lymphocytes, % CD4+ cells, and %
CD25hi FoxP3+ cells.
ELISpot for gp100, Mage-3, Melan-A and NA-17
Blood samples were collected before and every 3 cycles
on treatments. PBMC were isolated and frozen for
batched subsequent analysis. Direct ex vivo interferon
(IFN)-γ Elispot analysis was performed using cryopre-
served PBMC to assess for induction of antigen-specific
CD8+ T cell responses. Briefly, one vial of frozen PBMCs
from each time point was thawed and plated into anti-
IFN-γ antibody (clone 1-D1K, Mabtech, Inc) pre-coated
Elispot plate at 500,000 per well. Cells were then stimu-
lated with either EBV control peptide (Invitrogen, Inc.) or
one of the melanoma peptides, gp-100, Mage-3, Melan A,
and NA-17 (Multiple Peptide Systems), at 50 μM for 24 h
at 37 °C. Medium alone was used as negative control and
P + I (PMA+ Ionomycin) was used as positive control. For
P + I control wells, 5000 PBMC were plated per well. After
24 h, plates were washed and incubated with a biotinylated
anti-IFN-γ secondary Ab (clone 7-B6-1, Mabtech, Inc) for
2 h at room temperature, washed again and incubated with
streptavidin-conjugated AP for 1 h, washed, and incubated
with AP substrate. Excess substrate was removed by rinsing
with tap water. Plates were then captured and counted
using a CTL-ImmunoSpot S6 Core Analyzer from Cellular
Technology Ltd (Cleveland, OH). All samples were ana-
lyzed in triplicate, and the mean response to the negative
control was subtracted from each sample.
qRT-PCR for FoxP3 transcripts
Ribonucleic acid (RNA) was extracted from tumor biopsy
specimens using Trizol reagent (Invitrogen Inc.) according
to manufacturer’s instruction. The acquired RNA samples
were then used to make cDNA using High Fidelity cDNA
Synthesis Kit (Roche Applied Science), followed by qRT-
PCR using primer/probe sets specific for CD8 and FoxP3.
β-actin was used as the internal control. Primer sequences
for β-actin included: 5′-ggatgcagaaggagatcactg- 3′ and 5′ –
cgatccacacggagtacttg- 3′, probe sequence for β-actin: 5′ –
ccctggcacccagcacaatg- 3′. The primer sequences for CD8
included: 5′ –ccctgagcaactccatcatgt- 3′ and 5′ –gtgggcttcgc
tggca- 3′, the probe sequence for CD8: 5′ –tcagccacttcgtgc
cggtcttc- 3′. The primer sequences for FoxP3 included:
5′ – ggcactcctccaggacag- 3′ and 5′ –gctgatcatggctgggc
tct- 3′, the probe sequence for FoxP3: 5′ –atttcatgcac-
cagctctcaacggtgg- 3′. The qRT-PCR was run on an AB
I-7300 qPCR machine (Applied Biosystem).
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Statistical analysis
Analysis of pre-treatment and post-treatment biomarker
analytes was performed using paired student-t tests.
Results
Patient characteristics
The clinical characteristics of the 17 subjects accrued to
the study are shown in Table 1. Subjects were predomin-
ately male with a median age of 63 years and median
ECOG status of 1. The median number of prior therap-
ies was two with 83 % of subjects pretreated and 29 or
24 % having had prior treatment with interleukin-2 or
ipilimumab, respectively. The majority of the subjects
were M stage M1C (65 %) with 41 % having 3 or more
sites of disease.
Safety and clinical activity
There were 17 subjects enrolled, with 7 (41 %) random-
ized to denileukin diftitox and 10 (59 %) randomized to
vaccine only. Adverse reactions are listed in Table 2. All
subjects completed at least three cycles of therapy.
There were no grade 3 to 4 toxicities; grade 2 toxicities
included nausea in 2 subjects, fatigue and anorexia in
two other subjects. All other toxicities were grade 1 with
the most common adverse reactions being injection site
pain, headache and fatigue. All toxicities resolved spon-
taneously or with minimal palliative interventions.
Clinical response outcomes are listed in Table 3. One
subject who received vaccine only was noted to have a
RECIST response. Eight further subjects (4 receiving deni-
leukin diftitox and 4 without) were observed to show stable
disease as best response while 8 subjects demonstrated pro-
gressive disease only. No significant difference in time to
progression was observed between those randomized to
denileukin diftitox (4.9 months) as compared with those re-
ceiving vaccine only (4.4 months). Accrual was halted after
the first 17 patients were enrolled when the immune moni-
toring data failed to demonstrate an improvement in any
biologic endpoint with denileukin diftitox.
Evaluation of circulating Treg cells with and without
denileukin diftitox
While some previous studies suggested that denileukin
diftitox could reduce circulating Tregs, other studies did
not confirm this result [10, 11]. Because dose and sched-
ule were not identical in those trials, we chose a single
dose of denileukin diftotox given prior to the initiation of
vaccination. Subjects had pretreatment and on-treatment
blood samples collected 4 days following denileukin difti-
tox (or 4 days apart without intervention for the control
group). The number of circulating CD4+CD25hiFoxP3+
Treg cells was evaluated by flow cytometry. An example
of the flow cytometry gating strategy is shown in Fig. 1.
Table 1 Subject characteristics
Total study subjects 17
Age, median (Range), years 63 48–81
Sex Male 14 82 %
Female 3 18 %
ECOG PS pretreatment 0 8 47 %
1 9 53 %
Melanoma Sub-Type Cutaneous 15 88 %
Mucosal 2 3 %
Prior lines of therapy, n (%) 0 3 18 %
1 4 24 %
2 4 24 %
≥3 6 35 %
Median prior lines of therapy (% pretreated) 2 83 %
Prior Interleukin-2 5 29 %
Prior Ipilimumab 4 24 %
Number of metastatic sites 1 6 35 %
2 4 24 %
≥3 7 41 %
M1a 1 6 %
M1b 5 29 %
M1c 11 65 %
Table 2 Study-agent related adverse events
Adverse Event Grade 1 Grade 2 Grade 3–4
Injection Site Pain 10 0 0
Headache 6 0 0
Fatigue 6 1 0
Anorexia 1 1 0
Fever 2 0 0
Nausea 3 2 0
Rash 2 0 0
Infection 0 0 0
Respiratory 1 0 0
Hepatic 2 0 0
Thrombocytopenia 1 0 0
Anemia 1 0 0
Infection 1 0 0
Table 3 Clinical outcomes
Response Assessment Vaccine N = 10 DD + Vaccine N = 7 All N = 17
PR 1 (10 %) 0 1 (6 %)
SD 4 (40 %) 4 (57 %) 8 (47 %)
PD 5 (50 %) 3 (43 %) 8 (47 %)
Time to Progression 4.4 months 4.9 months 4.6 months
DD denileukin diftitox, PD progressive disease, PR partial response, SD stable disease
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No clear population of CD25+ cells was observed outside
the FoxP3 gate. As shown in Fig. 2, Treg numbers were
not reproducibly reduced after a single dose of denileukin
diftitox, and overall their frequencies were similar to those
seen in control patients who did not receive dinileukin dif-
titox. These data suggest that a single dose of denileukin
diftitox does not result in stable Treg cell depletion in the
peripheral blood.
Evaluation of changes in intratumoral FoxP3 transcripts
It was conceivable that Treg frequencies in the circula-
tion might not be depleted by denileukin diftitox but
that Tregs within the tumor microenvironment might
nonetheless be significantly affected. To this end, pre-
and post-treatment tumor biopsies were obtained in
eligible patients to explore effects on Treg presence in
the tumor microenvironment. We previously had shown
that FoxP3 transcripts assessed by qRT-PCR is a quanti-
tative assay with a broad dynamic range that reflects
Treg presence as assessed by IHC [12]. Therefore, FoxP3
qRT-PCR was utilized in the current study. Paired biop-
sies were obtained from 4 subjects based on accessible
lesions. Three of these patients (#7, 14, and 15) had been
randomized to the no-denileukin diftitox group. As
shown in Fig. 3, two of those patients showed increased
FoxP3 transcripts in the post-treatment biopsy while one
showed no change. One patient (#16) had been random-
ized to denileukin diftitox and showed increased FoxP3
transcripts in the post-treatment biopsy. Thus, while this
is a single subject having received denileukin diftitox, we
did not obtain evidence suggesting that Treg cells in the
tumor microenvironment were diminished.
Assessment of soluble circulating IL-2R-α
As denileukin diftitox is a recombinant fusion protein of
human IL-2 and diptheria toxin fragment, circulating IL-
2R-α could potentially neutralize denileukin diftitox
levels and potentially mitigate effects. Levels of IL-2R-α
were therefore evaluated in peripheral circulation by
ELISA assay of subjects in the study, to assess whether
levels were diminished following denileukin diftitox
administration. As shown in Fig. 4, no significant differ-
ences were seen in baseline levels between cohorts A
and B prior (p = 0.41) or after treatment (p = 0.26). No
significant differences were observed pre- or post-
treatment within either cohort with (cohort B, p = 0.13)
or without denileukin diftitox administration (cohort A,
p = 0.23) suggesting no major interaction between circu-
lating IL-2R-α and denileukin diftitox.
Fig. 1 Representative flow cytometric gating for CD4+CD25+FoxP3+ cells. Peripheral blood mononuclear cells were isolated using density gradient
centrifugation before and after patient received denileukin diftitox treatment versus no treatment. Cells were labeled with anti-CD4, anti-CD25, and
anti-FoxP3 Abs from the Treg staining kit (Miltenyi Biotech, Inc.) and then analyzed using a MACSQuant analyzer
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Evaluation of peptide-specific immune activation with
and without denileukin diftitox
One hypothesis leading to the rationale for this combin-
ation therapy was that the administration of denileukin
diftitox, through partial depletion of Tregs, might
augment the induction of antigen-specific CD8+ T cell
responses induced by vaccination. To investigate this
possibility, pre- and on-treatment peripheral blood was
analyzed by IFN-γ ELISPOT for the frequency of T cells
specific for gp100, Mage-3, Melan-A and NA-17. As
shown in Fig. 5, in the no-denileukin diftitox cohort, a
modest induction of peptide-specific CD8+ T cells was
detected following immunization in most patients, which
was statistically significant for the cohort (p = 0.0025,
Fig. 2 CD4+CD25hiFoxP3+ Treg in peripheral blood before and after denileukin diftitox treatment. Peripheral blood mononuclear cells were isolated using
density gradient centrifugation before and after patient received denileukin diftitox treatment versus no treatment. In the denileukin difitox arm, peripheral
blood mononuclear cells were isolated at the time of consent (pre) and before the first vaccination (post). Tregs were first labeled with anti-CD4, anti-CD25,
and anti-FoxP3 Abs from the Treg staining kit (Miltenyi Biotech, Inc.) and then analyzed using a MACSQuant analyzer. Paired student t-test was used to
determine whether there was a statistical difference between the pre- and post-treatment samples in each cohort
Fig. 3 Intratumoral FoxP3 mRNA transcripts before and after treatment with and without denileukin diftitox. Fresh biopsies was collected before and
after treatment when feasible and snap frozen in liquid nitrogen. RNA samples were isolated using the Trizol regent, and cDNA was synthesized using
the High Fidelity cDNA Synthesis Kit (Roche Applied Science). qRT-PCR was then performed to analyze the FoxP3 transcripts levels on ABI-7300 qPCR
instrument (Applied Biosystem). β-actin were used as an internal control
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paired t-test) and consistent with previous peptide vac-
cine studies [13, 14]. However, in contrast, no significant
increases in specific T cell responses was observed in the
denileukin diftitox cohort (p = 0.1246). Thus, in contrast
to our initial hypothesis, these results suggest that a sin-
gle dose of denileukin diftitox prior to this multipeptide
melanoma vaccine failed to augment vaccine-induced T
cell responses and in fact may have blunted them.
Discussion
Recent observations have indicated the functional import-
ance of immune inhibitory pathways in the tumor micro-
environment as being rate-limiting for immune-mediated
tumor control. A major subset of melanoma tumors shows
evidence for a T cell-inflamed tumor microenvironment at
baseline, which includes CD8+ T cells specific for melan-
oma antigens [12]. However, these same tumors show up-
regulation of programmed-death ligand-1 (PD-L1) and
indoleamine-2,3-dioxygenase (IDO) as well as infiltration
with CD4+FoxP3+ Tregs. These observations have provided
a rationale for developing immunotherapy strategies that
interfere with these immune suppressive pathways toward
restoring T cell function at the tumor site, including mono-
clonal antibodies blocking PD-L1/PD-1 interactions and
small molecule inhibitors of IDO. The preliminary suc-
cesses of these therapies have motivated renewed attention
to Tregs, and pursuit of novel therapeutics that deplete or
functionally inhibit Tregs has gained critical interest. In
mouse models, multiple strategies for Treg depletion have
shown therapeutic effects against growing tumors in vivo.
These include genetic ablation, depletion in vivo with anti-
CD25 monoclonal antibodies, or in vitro depletion prior to
adoptive T cell transfer [15]. Each of these manipulations
can improve immune-mediated tumor control either alone
or in combination with other immunotherapies [16, 17].
In the current study, the clinical and immunologic ef-
fects of a single dose of denileukin diftitox (as a strategy
to target CD25-expressing cells) prior to multi-peptide
vaccination were compared with multi-peptide vaccin-
ation alone in HLA-A2+ subjects with advanced melan-
oma. The treatment was well tolerated, however the
addition of denileukin diftitox did not improve vaccine-
induced immune responses and in fact may have inhib-
ited them. It is unclear how denileukin diftitox might
mechanistically be blunting the priming of CD8+ T cell
responses with vaccination, but it is tempting to
speculate that there may be a negative impact on
CD25-expressing activated CD8+ T cells. It appeared
that baseline T cell responses were diminished in the
denileukin diftitox cohort, which could imply that pre-
Fig. 4 Soluble interleukin-2 receptor-α in patients treated or untreated
with denileukin diftitox. Blood was drawn before and after subjects were
treated on the trial. Serum was aliquoted and stored at -80 °C until
analysis. Soluble interleukin-2 receptor (soluble CD25) levels were
analyzed by ELISA. Student t-test (assuming different variance in
each group) was used to determine whether there was a statistical
difference between the pre and post samples in each cohort and
between the two cohorts
Fig. 5 Circulating antigen-specific CD8+ T cells in patients treated or untreated with denileukin diftitox. Peripheral blood mononuclear cells were seeded
on anti-IFN-γ Ab-coated ELISPOT plates. 5 μM of peptide was then added to each well and incubated overnight. The plates were then incubated with the
biotin-labeled anti-IFN-γ Ab and developed according to manufacturer’s procedure. The plates were read and analyzed on CTL-ImmunoSpot S6 Core
Analyzer from Cellular Technology Ltd. Each point represents the numerical difference of Ag-specific CD8+ T cells in PBMCs post-vaccine and pre-treatment
for each patient. Each point represents an individual patient. Paired student t-test was used to determine whether there was a difference between the
pre- and post- samples in each cohort
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existing effector/memory cells might be depleted or
inhibited. While this difference did not reach statis-
tical significance, that could be limited by sample size.
Beyond immune response, no clinical impact was ob-
served, with comparable time to progression observed
in the two cohorts. Correlative analysis suggested that
there were no intra- or inter-cohort differences in
baseline or on-treatment soluble IL-2Rα. Finally, no
evidence was obtained that denileukin diftitox could
deplete intratumoral Tregs. Thus, although this was a
small study, we conclude that denileukin diftitox at
this dose and schedule is not an effective approach for
depleting Tregs and improving anti-tumor immunity
in patients. Our results are somewhat at odds with the
study from Dannull and colleagues, in which a single
dose of denileukin diftitox was given prior to vaccin-
ation in renal cell carcinoma patients, and suggested
to improve immunity [10]. However, that was a small
study and non-randomized, which could explain dif-
ferent outcomes. In addition, vaccine formulations
were different, with ours including only class I MHC
epitopes. Our data are consistent with those of Attia
et al. who found that denileukin diftitox given in mul-
tiple doses failed to deplete circulating CD4+CD25+
Treg cells [11]. In melanoma, a 60 patient phase II
study of denileukin diftitox, at 12 μg/kg in four daily
doses in every 21 day cycles, described a 16.7 % re-
sponse rate with improvement in 1 year survival of
subjects who experienced response [18]. While the
mechanism of that apparent clinical effect is unclear,
it is conceivable that there is a small subset of patients
that have the potential to derive clinical benefit from
this approach.
Other strategies to deplete or modulate Tregs in can-
cer patients are being explored and remain worthy of de-
velopment. Cyclophosphamide has long been suggested
to have modulating effects on Tregs, and ongoing clinical
trials are evaluating cyclophosphamide in combination
with anti-PD1/L1 antibody (Clinicaltrials.gov identifier
NCT02383212). Conceptually similar to denileukin difti-
tox, studies of the recombinant anti-CD25 immunotoxins
LMB-2 and RFT5-SMPT-dgA have suggested that Treg
populations can be transiently depleted. However, these
approaches have been limited by pharmacokinetic proper-
ties including brief half-lives and the development of
neutralizing antibodies [19, 20]. Anti-CD25 monoclonal
antibodies (daclizumab and basiliximab) have also been
investigated in human cancer clinical trials. Administra-
tion of daclizumab in conjunction with cancer vaccine
was associated with prolonged Treg depletion in periph-
eral blood and priming of CD8 and CD4 responses to vac-
cine antigens. The clinical impact of this was unclear
given the small sample size and comparison to historical
controls [21, 22]. Finally, monoclonal antibodies against
C-C chemokine receptor type 4 (CCR4) are being investi-
gated as an approach to deplete or modulate Tregs in
patients with cancer. The anti-CCR4 antibody mogamuli-
zumab has been shown to reduce peripheral Treg counts in
patients, leading to regulatory approval for the treatment of
peripheral T cell lymphomas in Japan [23]. This agent is be-
ing evaluated in conjunction with anti-PD1/L1, anti-
cytotoxic T lymphocyte antigen 4 and other immunother-
apies in multiple cancer histologies (Clinicaltrials.gov iden-
tifiers: NCT02476123, NCT02301130, NCT02444793).
Conclusions
In summary, this randomized study failed to demon-
strate that a single dose of denileukin diftitox could aug-
ment vaccine-specific immunity or improve clinical
outcomes in subjects with advanced melanoma. Contin-
ued investigation of the hypothesis that denileukin difti-
tox will specifically deplete Tregs via CD25 should be
discouraged, although other CD25-targeting approaches
may be of interest. Broadly speaking, novel strategies for
depleting or modulating Tregs in cancer patients as an
immunotherapeutic strategy should remain a high prior-
ity for development.
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programmed-death ligand-1; also known as cluster of differentiation 274, a
molecule that plays a major role in suppressing immune reponses; RECIST,
Response Evaluation In Solid Tumor; a set of criteria to evaluate the
effectiveness of cancer treatment; Treg, regulatory T cell; a population of
immune cells that maintains tolerance to self-antigens
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